  Recently, the SARS-CoV-2 variants from the United Kingdom (UK), South Africa,
and Brazil have received much attention for their increased infectivity,
potentially high virulence, and possible threats to existing vaccines and
antibody therapies. The question remains if there are other more infectious
variants transmitted around the world. We carry out a large-scale study of
252,874 SARS-CoV-2 genome isolates from patients to identify many other rapidly
growing mutations on the spike (S) protein receptor-binding domain (RDB). We
reveal that 88 out of 95 significant mutations that were observed more than 10
times strengthen the binding between the RBD and the host
angiotensin-converting enzyme 2 (ACE2), indicating the virus evolves toward
more infectious variants. In particular, we discover new fast-growing RBD
mutations N439K, L452R, S477N, S477R, and N501T that also enhance the RBD and
ACE2 binding. We further unveil that mutation N501Y involved in United Kingdom
(UK), South Africa, and Brazil variants may moderately weaken the binding
between the RBD and many known antibodies, while mutations E484K and K417N
found in South Africa and Brazilian variants can potentially disrupt the
binding between the RDB and many known antibodies. Among three newly identified
fast-growing RBD mutations, L452R, which is now known as part of the California
variant B.1.427, and N501T are able to effectively weaken the binding of many
known antibodies with the RBD. Finally, we hypothesize that RBD mutations that
can simultaneously make SARS-CoV-2 more infectious and disrupt the existing
antibodies, called vaccine escape mutations, will pose an imminent threat to
the current crop of vaccines. A list of most likely vaccine escape mutations is
given, including N501Y, L452R, E484K, N501T, S494P, and K417N.
